The Cancer Research Technology Pioneer Fund is making its ninth investment in a project aiming to develop a new class of therapies for patients with diffuse large B-cell lymphoma - a sub-type of Non-Hodgkin Lymphoma (NHL).
The treatment scope of Novartis' Lucentis has been expanded in Europe to include patients with visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD), or secondary to pathologic myopia (PM).
Survival rates following lung cancer surgery are continuing to rise as the number of operations to treat the disease increases, finds a new report published by the Royal College of Physicians (RCP) and the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS).
Late-stage data show that AstraZeneca's Tagrisso extended the time lung cancer patients carrying a particular mutation lived without their disease worsening, potentially signalling a new standard of care in the second-line setting.
NHS England's chief executive Simon Stevens has unveiled the first tranche of hospitals that will benefit from a major national investment in NHS radiotherapy machines, as well as a £200m fund to improve cancer services.
Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes.